- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03112044
Lung Transplant HCV, Pilot Study
December 5, 2023 updated by: University Health Network, Toronto
Lung Transplantation Using Hepatitis C Positive Donors to Hepatitis C Negative Recipients: A Pilot Study
In this study HCV negative recipients will be transplanted with HCV positive lungs.
Investigators will attempt to decrease infectivity rates by performing Normothermic Ex vivo Lung Perfusion (EVLP), which is an approved method of donor lung preservation, assessment and treatment, and could be an excellent platform to reduce/eliminate hepatitis C virus.
Patients will be treated by the standard approved direct-acting antivirals (DAAs) if infection occurs.
It is planned to enrolled 20 patients from the Lung transplant wait list in this study.
Patients will be followed for 6 months.
This will be a single center pilot study.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
The success of lung transplantation (LTx) is significantly hindered by the lack of sufficient number of available donors.
Many potential donor lungs cannot be utilized in clinical transplantation because donors have chronic viral infections such as hepatitis C (HCV) infection.
This study will test the possibility of safely transplanting lungs from HCV positive donors.
Donor lungs will be subjected to Normothermic Ex vivo Lung Perfusion (EVLP) for 6 hours for organ assessment and reduction of viral load prior to transplantation.
After transplantation, recipients will be carefully monitored for HCV infection and if infection occurs, they will be promptly treated with highly effective antiviral therapy using newly approved DAAs.
The aim of the study is to show that transplantation of lungs from HCV positive donors is safe in the era of DAAs.
The hypothesis is that the rate of HCV transmission to recipients will be lower than previously described due to EVLP pre-treatment and any HCV transmission that does occur will be readily treatable and curable.
If successful, the knowledge from this study can have a large impact to patients with end stage organ diseases by providing a large novel source of donors for lung and potentially other organ transplantations.
Study Type
Interventional
Enrollment (Actual)
26
Phase
- Early Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2N2
- University Health Network Toronto General Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Recipients listed for single or bilateral lung transplant
- HCV Nucleic Acid Amplification Testing (NAT) negative
- Ability to provide written informed consent
Exclusion Criteria:
- Participation in another interventional clinical trial
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HCV+ lung transplant to HCV- recipients
HCV+ donor lungs will be treated with Normothermic Ex Vivo Lung Perfusion (EVLP) in order to reduce viral load and minimize risk of HCV transmission.
Patients who become viremic defined as at least two consecutive positive samples will receive sofosbuvir/velpatasvir 400 mg/100 mg (Epclusa) for 12 weeks.
|
Patients will have standard monitoring with HCV RNA and liver panel assessment at 2 week intervals until HCV is undetectable and then at the end of treatment and 3 and 6 months following its completion.
Post-operative transplant care and immunosuppression will be carried on as usual transplant practice at Toronto General Hospital.
Other Names:
Normothermic EVLP is a method of donor lung preservation, assessment, treatment, and repair of injured organs.
This method allows donor lungs to be treated for at least 12h under protective physiological conditions.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety of transplantation from HCV positive donors to HCV negative recipients
Time Frame: 6 months
|
Safety of transplantation using HCV positive donors reflected by 6 month survival and being free of HCV by PCR (either due to lack of transmission or as a result of treatment).
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of HCV transmission
Time Frame: 6 months
|
Incidence of donor to recipient HCV transmission.
|
6 months
|
Correlation between viral loads and recipient infection
Time Frame: 6 months
|
Correlation between donor viremia, EVLP perfusate virus load (PCR), lung tissue virus load at the end of EVLP (PCR) and recipient infection
|
6 months
|
Time to viremia development
Time Frame: 6 months
|
Interval of time from transplantation to development of viremia
|
6 months
|
HCV cure rates
Time Frame: 6 months
|
HCV cure rates after treatment of infected patients
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Marcelo Cypel, MD MSc FRCSC, University Health Network, Toronto
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 19, 2017
Primary Completion (Actual)
January 2, 2020
Study Completion (Estimated)
December 31, 2024
Study Registration Dates
First Submitted
April 6, 2017
First Submitted That Met QC Criteria
April 11, 2017
First Posted (Actual)
April 13, 2017
Study Record Updates
Last Update Posted (Actual)
December 6, 2023
Last Update Submitted That Met QC Criteria
December 5, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Liver Diseases
- Flaviviridae Infections
- Hepatitis, Viral, Human
- Enterovirus Infections
- Picornaviridae Infections
- Hepatitis
- Hepatitis A
- Hepatitis C
- Anti-Infective Agents
- Antiviral Agents
- Sofosbuvir
- Sofosbuvir-velpatasvir drug combination
- Velpatasvir
Other Study ID Numbers
- 16-6084
- UHNTID006 (Other Identifier: Tx ID research)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatitis C
-
Tripep ABInovio PharmaceuticalsUnknownChronic Hepatitis C Virus InfectionSweden
-
Hadassah Medical OrganizationXTL BiopharmaceuticalsWithdrawnChronic Hepatitis C Virus InfectionIsrael
-
Hadassah Medical OrganizationUnknownChronic Hepatitis C Virus InfectionIsrael
-
AbbVieCompletedChronic Hepatitis C | Hepatitis C (HCV) | Hepatitis C Genotype 1a
-
AbbVie (prior sponsor, Abbott)CompletedChronic Hepatitis C | Hepatitis C Genotype 1 | Hepatitis C (HCV)United States, Australia, Canada, France, Germany, New Zealand, Puerto Rico, Spain, United Kingdom
-
AbbVieCompletedHepatitis C Virus | Chronic Hepatitis C Virus
-
AbbVie (prior sponsor, Abbott)CompletedHepatitis C | Chronic Hepatitis C Infection | HCV | Hepatitis C Genotype 1United States
-
Trek Therapeutics, PBCCompletedChronic Hepatitis C | Hepatitis C Genotype 1 | Hepatitis C (HCV) | Hepatitis C Viral InfectionUnited States, New Zealand
-
Trek Therapeutics, PBCCompletedChronic Hepatitis C | Hepatitis C (HCV) | Hepatitis C Genotype 4 | Hepatitis C Viral InfectionUnited States
-
Beni-Suef UniversityCompletedChronic Hepatitis C Virus InfectionEgypt
Clinical Trials on Sofosbuvir-velpatasvir (400 mg/100 mg)
-
Instituto Nacional de Ciencias Medicas y Nutricion...Gilead SciencesNot yet recruitingHepatitis C in Substance Users
-
Catherine Anne ChappellGilead SciencesRecruitingHepatitis C, Chronic | Pregnancy; InfectionUnited States, Canada
-
Hannover Medical SchoolGilead Sciences; HepNet Study House, German Liverfoundation; German Center for...CompletedHepatitis C | Acute Hepatitis CGermany
-
Queen Mary University of LondonUniversity of Oxford; Aga Khan University; University of Bristol; Dow University...Enrolling by invitation
-
Ohio State UniversityCompletedHepatitis C | HCV | Kidney TransplantUnited States
-
Right to CareBoston University; University of California, Los Angeles; Ministry of Health... and other collaboratorsCompletedHIV Infections | Hepatitis B | Hepatitis CMyanmar
-
Kirby InstituteRecruitingHepatitis C | Liver Cirrhoses | Liver InflammationAustralia
-
National Taiwan University HospitalRecruitingHepatitis C Virus Infection | Treatment Side Effects | Effect of Drug | Adherence, TreatmentTaiwan
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.CompletedAsthma; Allergic RhinitisChina
-
ANRS, Emerging Infectious DiseasesCompletedHepatitis C | Viral Hepatitis C | Drug UseVietnam